Farms.com Home   News

MN Corn-Funded Pilot Succeeds: Valerian to Commercialize Its Corn-Based Monomer

By Jonathan Eisenthal

Advanced materials firm Valerian Materials is creating a new molecule that will be used to make recyclable plastic derived from corn. The young company has taken a significant step towards commercialization, following a pilot plant scale production run funded by a grant from Minnesota Corn Research & Promotion Council.

The grant allowed Valerian to conduct test production runs in a facility in Augusta, Georgia, where they made use of 300-liter fermentation tanks—a major scale up from earlier bench lab tests made using 5-liter vessels.

Valerian CEO Mike Arbeiter said the company has just concluded an investment round and is ready “to begin producing material at demo scale for customers that are seeking sample material from us.”

He anticipates commercial revenue to flow in from sales in 2026, and he credits the Minnesota Corn investment for helping Valerian assess cost factors and begin to plan their scale-up, so they can be fully competitive with fossil fuel-sourced plastics.

NuvoneÒ, the proprietary monomer innovated by Valerian, could serve as the basic building block for anything from foam used in products like yoga mats and seat cushions, elastomers in things like rubber bands and leggings, the polymers used in plastic cups, or material for athletic shoe soles. Nuvone is derived through a fermentation process using corn. Beyond being recyclable and compostable, one of Nuvone’s most appealing characteristics is that it is regenerative. For instance, when the athletic shoe is worn out, the sole can be chemically recycled to capture back the original Nuvone monomer, for re-use over and over again. There are tremendous implications for the reduction of fossil fuel use, and greenhouse gas emissions.

Click here to see more...

Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.